Machine Learning for Predicting the Risk of Transition from Prediabetes to Diabetes.


Journal

Diabetes technology & therapeutics
ISSN: 1557-8593
Titre abrégé: Diabetes Technol Ther
Pays: United States
ID NLM: 100889084

Informations de publication

Date de publication:
11 2022
Historique:
pubmed: 19 7 2022
medline: 4 11 2022
entrez: 18 7 2022
Statut: ppublish

Résumé

Traditional risk scores for the prediction of type 2 diabetes (T2D) are typically designed for a general population and, thus, may underperform for people with prediabetes. In this study, we developed machine learning (ML) models predicting the risk of T2D that are specifically tailored to people with prediabetes. We analyzed data of 13,943 individuals with prediabetes, and built a ML model to predict the risk of transition from prediabetes to T2D, integrating information about demographics, biomarkers, medications, and comorbidities defined by disease codes. Additionally, we developed a simplified ML model with only eight predictors, which can be easily integrated into clinical practice. For a forecast horizon of 5 years, the area under the receiver operating characteristic curve was 0.753 for our full ML model (79 predictors) and 0.752 for the simplified model. Our ML models allow for an early identification of people with prediabetes who are at risk of developing T2D.

Identifiants

pubmed: 35848962
doi: 10.1089/dia.2022.0210
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

842-847

Auteurs

Thomas Zueger (T)

Department of Diabetes, Endocrinology, Nutritional Medicine, and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Endocrinology and Metabolic Diseases, Kantonsspital Olten, Olten, Switzerland.

Simon Schallmoser (S)

Institute of AI in Management, LMU Munich, Munich, Germany.

Mathias Kraus (M)

Institute of Information Systems, FAU Erlangen-Nuremberg, Nuremberg, Germany.

Maytal Saar-Tsechansky (M)

The McCombs School of Business, The University of Texas at Austin, Austin, Texas, USA.

Stefan Feuerriegel (S)

Institute of AI in Management, LMU Munich, Munich, Germany.

Christoph Stettler (C)

Department of Diabetes, Endocrinology, Nutritional Medicine, and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH